Publication:
The effect of risedronate treatment on serum osteoprotegerin and bone marker levels in postmenopausal women with osteoporosis

Simple item page
dc.contributor.authorAKYÜZ, GÜLSEREN DERYA
dc.contributor.authorsKaradag-Saygi, Evrim; Akyuz, Gulseren; Bizargity, Peyman; Ay, Pinar
dc.date.accessioned2022-03-12T17:52:57Z
dc.date.available2022-03-12T17:52:57Z
dc.date.issued2011
dc.description.abstractBackground. To evaluate the effect of risedronate treatment on osteoprotegerin (OPG), C-terminal cross-linking telopeptide of type 1 collagen (CTX), osteocalcin (OC), and deoxypyridinoline (DPD). Methods. Eighty postmenopausal osteoporotic patients were randomized into two groups. In first group, patients received 35 mg of risedronate once a week and calcium with vitamin D per day. In second group, patients received only calcium with vitamin D per day. Bone turnover markers were measured at baseline, 1st, 3rd and 6th month. Results. OPG levels were significantly reduced at 1st and 6th month of treatment in both groups, but no statistically significant difference was detected between groups. In the group treated with risedronate, difference in CTX level was observed at 3rd month of treatment, while a difference in DPD and OC levels were observed at 6th month of treatment. The baseline OPG levels correlated with age, menopause duration, and CTX levels. There was no correlation between OPG levels and the levels of the other markers during treatment. Conclusion. The present study showed that using risedronate in treatment of postmenopausal osteoporosis causes no specific changes in OPG levels; therefore, in contrast to some of the studies in the literature OPG may not be useful marker in monitoring of bisphosphonate.
dc.identifier.doi10.3109/09513590.2011.579657
dc.identifier.eissn1473-0766
dc.identifier.issn0951-3590
dc.identifier.pubmed21627558
dc.identifier.urihttps://hdl.handle.net/11424/230435
dc.identifier.wosWOS:000296777700014
dc.language.isoeng
dc.publisherTAYLOR & FRANCIS LTD
dc.relation.ispartofGYNECOLOGICAL ENDOCRINOLOGY
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectOsteoporosis
dc.subjectrisedronate
dc.subjectosteoprotegerin
dc.subjectbone marker
dc.subjectSOLUBLE RECEPTOR ACTIVATOR
dc.subjectFACTOR-KAPPA-B
dc.subjectDISEASE-ACTIVITY
dc.subjectMINERAL DENSITY
dc.subjectPAGETS-DISEASE
dc.subjectLIGAND
dc.subjectTURNOVER
dc.subjectFRACTURES
dc.subjectTHERAPY
dc.subjectMASS
dc.titleThe effect of risedronate treatment on serum osteoprotegerin and bone marker levels in postmenopausal women with osteoporosis
dc.typearticle
dspace.entity.typePublication
local.avesis.id1ccdfe05-0de5-40bf-9636-4f8a914768de
local.import.packageSS17
local.indexed.atWOS
local.indexed.atSCOPUS
local.indexed.atPUBMED
local.journal.numberofpages4
oaire.citation.endPage1036
oaire.citation.issue12
oaire.citation.startPage1033
oaire.citation.titleGYNECOLOGICAL ENDOCRINOLOGY
oaire.citation.volume27
relation.isAuthorOfPublicationa0d3ad8e-a3dd-44d0-98b7-d3eb31f6a0c9
relation.isAuthorOfPublication.latestForDiscoverya0d3ad8e-a3dd-44d0-98b7-d3eb31f6a0c9

Files

Collections

Research Outputs